Core Viewpoint - 加科思药业 has seen significant management confidence through recent share buybacks and purchases, indicating a belief in the undervaluation of the company and its pipeline potential [1][4] Group 1: Shareholder Actions - 加科思药业 announced that its concerted parties have recently increased their holdings by 854,400 shares at an average price of HKD 5.88 per share, totaling over HKD 5 million [1] - The company does not rule out the possibility of further share purchases in the future [1] - The management's high-level purchases reflect a strong belief in the company's value and pipeline confidence, especially after a 427% increase in stock price year-to-date [1] Group 2: Product Pipeline and Market Potential - The company's most notable product, the KRAS inhibitor JAB-23E73, has entered Phase I trials in China and the U.S., with a global sales peak potential of USD 12.1 billion, particularly in pancreatic and non-small cell lung cancers [2] - JAB-23E73 is a small molecule oral drug with promising pharmacokinetics and significant anti-tumor activity, showing a cost advantage over competitors [3] - 加科思's market capitalization is currently at HKD 5 billion, significantly lower than Revolution Medicine's USD 7 billion, indicating substantial upside potential [3] Group 3: Financial Outlook and Revenue Generation - The approval of the KRAS G12C inhibitor, 戈来雷塞, marks a critical milestone for 加科思, expected to generate stable cash flow through its commercialization [4] - 戈来雷塞 is priced at approximately HKD 38,000 per month, with a potential market size of HKD 6 billion based on patient demographics and market share estimates [4] - The strategic partnership with 艾力斯 for sales in China could yield approximately HKD 200 million annually from milestone and sales sharing, providing solid performance support for the company's current valuation [5] Group 4: Future Developments - The SHP2 inhibitor JAB-3312 is the first of its kind to enter Phase III trials, with potential implications for first-line treatment of non-small cell lung cancer, which could trigger additional milestones for 艾力斯 and become a new revenue source [6]

加科思-B公告，于2025年7月16日至7月18日，一致行动人士在公开市场以5.88港元的平均每股价格买入 合计85.44万股。此次增持后，一致行动人士共持有公司2亿股股份，约占已发行股份总数的25.32%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 JACOBIO PHARMACEUTICALS GROUP CO., LTD. 加 科 思 藥 業 集 團 有 限 公 司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：1167） 自願公告 一致行動人士增持股份 本公告由加科思藥業集團有限公司（「本公司」或「加科思」，連同其附屬公司，統稱「本集 團」）自願刊發，以告知本公司股東及潛在投資者有關本公司一致行動人士（「一致行動人士」） 權益變動的情況。 本公司董事會（「董事會」）已獲公司一致行動人士成員告知，於2025年7月16日至7月18日， 彼等已於公開市場按5.88港元的平均每股價格買入合計854,400股本公司股份（「股份」）。 緊隨此次持股增加之後，截至本公告日期，一致行動人士共持有本公司200,454,385股股份， 約佔本公司已發行股份總數的25.32%。 上述一致行動人士成員表示對本公司的整體發展前景、增長潛力 ...

Market Performance - A-shares steadily advanced this week, with the ChiNext Index reaching a new high for the year and the Shenzhen Component Index hitting a four-month high, approaching its highest point of the year [1] - Weekly trading volume increased to 7.73 trillion yuan, marking the largest weekly trading volume in three months [1] Fund Inflows - Leverage funds actively entered the market, with most industries under the Shenwan first-level industry classification seeing net buying, particularly the computer industry with over 4.4 billion yuan and the electronics industry with over 3 billion yuan [2] - The electronic, biopharmaceutical, and automotive sectors each received over 20 billion yuan in net inflows, while the non-bank financial sector saw a net outflow of over 8.3 billion yuan [2] Rare Earth Demand - The rare earth sector performed strongly, with the rare earth permanent magnet index reaching a three-and-a-half-year high [3] - Demand for rare earths is expected to grow rapidly due to advancements in humanoid robots and electric vehicles, with estimates suggesting a demand of at least 70,000 tons of neodymium-iron-boron by 2025 [3] Energy Metals - The energy metals sector, including lithium and cobalt, reached a two-year high, with lithium carbonate futures breaking 70,000 yuan/ton, marking a 20% increase from recent lows [4] - Short-term lithium salt supply may decline due to reduced exports from Chile and domestic production halts, leading to a potential price stabilization [4] Biopharmaceutical Sector - The biopharmaceutical sector saw significant gains, with the innovative drug index hitting record highs multiple times this week [6] - Notable stocks in the sector, such as Lianhuan Pharmaceutical and Aosaikang, experienced consecutive trading halts, with some stocks showing year-to-date gains exceeding 200% [6][7] Earnings Forecasts - Several pharmaceutical companies have recently forecasted substantial profit increases for the first half of 2025, with estimates suggesting net profit growth exceeding 19 times for some firms [7]

Group 1 - Hong Kong biopharmaceutical stocks have strengthened again, with Lepu Biopharma (02157.HK) and Genscript Biotech (01672.HK) both rising by 9% [1] - Other companies such as Kintor Pharmaceutical (01167.HK) and Qianxin Biopharma (02509.HK) have seen increases of over 7% [1]

Group 1 - The article reports on stock buybacks conducted by various companies on July 15, 2025, with a total of 20 companies participating in the buyback program [1] - The company with the largest buyback amount was Wan Ka Yi Lian (01762), repurchasing 7.14 million shares for a total of 5.06 million yuan [1][2] - Other notable buybacks include Mengniu Dairy (02319) with 300,000 shares for 4.97 million yuan and China International Marine Containers (02039) with 613,100 shares for 4.03 million yuan [2] Group 2 - The cumulative buyback figures for the year show Wan Ka Yi Lian (01762) has repurchased a total of 17.37 million shares, representing 0.981% of its total share capital [2] - Other companies with significant cumulative buyback percentages include Kangchen Pharmaceutical (01681) at 5.926% and China Aluminum Can (06898) at 3.900% [2] - The buyback activity reflects a strategic move by these companies to enhance shareholder value and signal confidence in their financial health [1][2]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 加科思藥業集團有限公司 呈交日期： 2025年7月15日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 01167 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 事件 | 已發行股份（不包 ...

Group 1 - The company intends to exercise the general mandate granted by shareholders at the annual general meeting on June 10, 2025, to repurchase up to 78.8735 million shares, representing 10% of the total issued shares as of that date [1] - The board has decided to utilize the share repurchase mandate and plans to buy back shares in the open market using up to HKD 100 million, funded by its own financial resources [1][2] - The company believes that the current trading price of its shares does not reflect their intrinsic value, and the proposed share repurchase could enhance share value and increase returns for shareholders [2] Group 2 - The board expresses confidence in the company's long-term business prospects and growth potential, indicating that the share repurchase aligns with the best interests of the company and its shareholders [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 JACOBIO PHARMACEUTICALS GROUP CO., LTD. 加 科 思 藥 業 集 團 有 限 公 司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：1167） 自願公告 擬進行市場內股份購回 本公司將根據本公司組織章程細則、香港聯合交易所有限公司證券上市規則（「上市規則」）、 公司收購、合併及股份購回守則、開曼群島公司法及本公司須遵守的所有適用法律及法 規進行建議股份購回，每股股份的實際購回價格不得高於股份於緊接每次購回前五個交 易日的平均收市價的5%。本公司或會根據市況進一步購回股份，直至股份購回授權屆滿 為止，但於任何情況下均以股份購回授權為限。建議股份購回不會導致公眾人士所持有 的股份數目降至低於上市規則所規定的相關最低百分比。任何根據建議股份購回所購回 的股份可能被注銷或作為庫存持有。 本公司各項業務發展及運營一切正常，現時的財務狀況穩健。董事 ...

JACOBIO PHARMACEUTICALS GROUP CO., LTD. 加 科 思 藥 業 集 團 有 限 公 司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 關於加科思 （股份代號：1167） 自願公告 加科思完成泛KRAS抑制劑JAB-23E73 I/IIa期 臨床試驗在美國的首例患者給藥 本公告由加科思藥業集團有限公司（「本公司」或「加科思」，連同其附屬公司，統稱「本集 團」）自願刊發，以告知本公司股東及潛在投資者有關本集團最新業務發展的資料。 本公司董事（「董事」）會（「董事會」）欣然宣佈，本公司自主研發的泛KRAS抑制劑JAB- 23E73在美國完成I/IIa期臨床試驗首例患者給藥。目前該藥物在中國的劑量遞增研究也正 按計劃順利推進。 KRAS是最常導致致癌突變的基因之一，約23%-25%的癌症患者帶有KRAS突變，其在胰 腺癌（約90%）、結直腸癌（約40%）和非小細胞肺癌（約30%）中突變頻率尤為顯著。全球每 年新增約270 ...